| scholarly article | Q13442814 |
| P2093 | author name string | Michael N Pollak | |
| Laurent Azoulay | |||
| Samy Suissa | |||
| Kristian B Filion | |||
| Hui Yin | |||
| Agnieszka Majdan | |||
| Jonathan Assayag | |||
| P2860 | cites work | Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure | Q24799850 |
| Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study | Q24799963 | ||
| Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells | Q28345289 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 | ||
| Adaptation and validation of the Charlson Index for Read/OXMIS coded databases | Q33522043 | ||
| Validation of information recorded on general practitioner based computerised data resource in the United Kingdom | Q33539292 | ||
| Clinical information for research; the use of general practice databases | Q33755703 | ||
| Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats | Q33800079 | ||
| Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. | Q34086275 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 | ||
| Diabetes and risk of bladder cancer: evidence from a case-control study in New England | Q35051024 | ||
| Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation | Q35230678 | ||
| The nested case-control study in cardiology | Q35562147 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| Use of the UK General Practice Research Database for pharmacoepidemiology | Q35802395 | ||
| Validation of the diagnosis of venous thromboembolism in general practice database studies | Q36055463 | ||
| Diabetes mellitus and risk of bladder cancer: a meta-analysis | Q36615062 | ||
| Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin | Q37117876 | ||
| Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. | Q40669494 | ||
| Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death | Q41970353 | ||
| Rosiglitazone, PPARγ, and type 2 diabetes | Q42536949 | ||
| Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 | ||
| Validity of the General Practice Research Database | Q47921352 | ||
| Evaluating Medication Effects Outside of Clinical Trials: New-User Designs | Q52956338 | ||
| Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. | Q53338744 | ||
| Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus | Q59656664 | ||
| The UK General Practice Research Database | Q77357717 | ||
| Pioglitazone and bladder cancer | Q82248231 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | e3645 | |
| P577 | publication date | 2012-05-30 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | |
| P478 | volume | 344 |
| Q42824273 | 6-gingerol inhibits rosiglitazone-induced adipogenesis in 3T3-L1 adipocytes |
| Q28074377 | A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. |
| Q34181385 | A Review on the Relationship between SGLT2 Inhibitors and Cancer. |
| Q38193601 | A review on thiazolidinediones and bladder cancer in human studies |
| Q38072616 | Advances in pharmacologic therapies for type 2 diabetes |
| Q34427860 | An introduction to the fundamentals of cohort and case-control studies |
| Q62495446 | Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects |
| Q58966970 | Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study |
| Q84457506 | Bladder cancer: Pioglitazone increases risk of bladder cancer |
| Q27002540 | Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis |
| Q30242051 | Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? |
| Q58815362 | Carcinogenicity of some drugs and herbal products |
| Q37161933 | Cardiometabolic interventions - focus on transcriptional regulators |
| Q37058711 | Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013 |
| Q35884562 | Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system |
| Q35964678 | Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins |
| Q37718287 | Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin |
| Q40141299 | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes |
| Q37115436 | Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q39101221 | Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes |
| Q35135876 | Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series |
| Q37193648 | Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. |
| Q33714881 | Diabetes medications and cancer risk: review of the literature |
| Q46942509 | Diabetes mellitus and non-muscle-invasive bladder cancer: not just a coincidence? |
| Q86316589 | Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies |
| Q37593873 | Distinguishing incident and prevalent diabetes in an electronic medical records database |
| Q38092275 | Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? |
| Q37577159 | Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. |
| Q53060957 | Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study. |
| Q38414756 | Effect of pioglitazone medication on the incidence of dementia |
| Q40468893 | Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. |
| Q37624930 | Endothelium as a gatekeeper of fatty acid transport |
| Q38058381 | Examining the safety of PPAR agonists - current trends and future prospects |
| Q34685755 | Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer |
| Q87704839 | Fibrates and risk of cancer in tissues with high PPAR-α concentration: a nested case-control study |
| Q38055296 | Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. |
| Q28829259 | Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature |
| Q35144348 | Genetic polymorphisms in the CYP1A1 and CYP1B1 genes and susceptibility to bladder cancer: a meta-analysis |
| Q28546721 | Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study |
| Q45073276 | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes |
| Q37577111 | Guideline approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q61799673 | High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone |
| Q35628554 | High glucose promotes gastric cancer chemoresistance in vivo and in vitro |
| Q58811102 | Hyperinsulinaemic androgen excess in adolescent girls |
| Q57559137 | In reply |
| Q55045262 | In-Hospital Implementation of Evidence-Based Medications is Associated with Improved Survival in Diabetic Patients with Acute Coronary Syndrome - Data from TSOC ACS-DM Registry. |
| Q36635502 | Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study |
| Q36410079 | Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients |
| Q45330314 | Insulin resistance: a risk marker for disease and disability in the older person |
| Q36417868 | Insulin therapy and cancer in type 2 diabetes |
| Q92211590 | Investigating the risk of bone fractures in elderly patients with type 2 diabetes mellitus: a retrospective study |
| Q33588852 | Latest insights into the risk of cancer in diabetes |
| Q43242358 | Letter: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8). |
| Q36365216 | Management of type 2 diabetes mellitus in older adults |
| Q36082226 | Metformin as an anticancer drug: A Commentary on the metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
| Q34782184 | Miniature short hairpin RNA screens to characterize antiproliferative drugs |
| Q44573861 | Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease |
| Q92524582 | NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression |
| Q35817986 | Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality |
| Q28553592 | Opportunities and Challenges in Developing a Cohort of Patients with Type 2 Diabetes Mellitus Using Electronic Primary Care Data |
| Q33577712 | Optimal therapy of type 2 diabetes: a controversial challenge |
| Q35711530 | PPARγ Ligands Attenuate Hypoxia-Induced Proliferation in Human Pulmonary Artery Smooth Muscle Cells through Modulation of MicroRNA-21. |
| Q37407887 | PPARγ signaling and metabolism: the good, the bad and the future |
| Q39376180 | Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales |
| Q42098281 | Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer |
| Q37690079 | Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial |
| Q35395528 | Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands |
| Q38588344 | Pharmacotherapy for Nonalcoholic Fatty Liver Disease |
| Q38417421 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis |
| Q55079635 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. |
| Q41825937 | Pioglitazone and bladder cancer: two studies, same database, two answers |
| Q37576689 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis |
| Q34324440 | Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies |
| Q46868396 | Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter]. |
| Q38721611 | Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis |
| Q38282651 | Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit |
| Q36004698 | Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals |
| Q45974480 | Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. |
| Q30490577 | Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study |
| Q91875408 | Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies |
| Q34676639 | Pioglitazone use and risk of bladder cancer: population based cohort study |
| Q55406042 | Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. |
| Q37015940 | Pioglitazone: A prudent prescription |
| Q92379649 | Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication |
| Q33739454 | Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. |
| Q28554260 | Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada |
| Q38983318 | Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics |
| Q54312687 | Preventive roles of swimming exercise and pioglitazone treatment on hepatic dysfunction in a rat model of metabolic syndrome. |
| Q36105361 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). |
| Q38219491 | Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus |
| Q57076958 | Report of the JDS/JCA Joint Committee on Diabetes and Cancer |
| Q50488148 | Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. |
| Q36490156 | Response: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8). |
| Q34098318 | Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy |
| Q37583052 | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. |
| Q44980532 | Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study |
| Q38091380 | Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes |
| Q38103131 | Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus |
| Q36581133 | Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. |
| Q38122640 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? |
| Q28536366 | Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease |
| Q41107308 | Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes |
| Q58584097 | The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond |
| Q38752520 | The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q34511545 | The durability of sitagliptin in elderly patients with type 2 diabetes |
| Q38062033 | The impact of current and novel anti-diabetic therapies on cardiovascular risk |
| Q38275171 | The ongoing pursuit of neuroprotective therapies in Parkinson disease |
| Q47360637 | The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study. |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q34065266 | Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis |
| Q34315432 | Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. |
| Q38250185 | Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease |
| Q42938702 | Thiazolodinediones and cancer: duplicate publication bias? |
| Q33756414 | Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy |
| Q26750845 | Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs |
| Q35910429 | Update on Safety Issues Related to Antihyperglycemic Therapy |
| Q38036778 | Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease |
| Q35466765 | Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article |
| Q52717838 | Valsartan Alleviates Insulin Resistance in Skeletal Muscle of Chronic Renal Failure Rats. |
Search more.